Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

The Cue from USDX That Gold Didn’t Take

In Friday’s Alert, we warned that gold and USD movement in the next few days might be a bit chaotic due to the geopolitical news that are currently hitting the markets. The new steps in the Brexit saga and the U.S.-China agreement continue to support intraday v...
Przemyslaw Radomski, CFA | December 17, 2019 |

Here Comes Another $2T Support for Stocks

In anticipation of the previous $2T stimulus package that passed on Mar 27 and in its aftermath, stocks rallied, yet it wasn’t a one-way road. They had trouble overcoming the pre-stimulus highs, and actually sold off in the following week. Today&CloseCurly...
Monica Kingsley | April 9, 2020 |

Dangerous Strength in the Gold Stocks

We previously wrote about the situation being similar to 2012 with regard to overall price movement in gold and in particular with regard to the 61.8% Fibonacci retracement that has been just reached. The yellow metal declined by a few dollars yesterday, just like it did after...
Przemyslaw Radomski, CFA | March 27, 2019 |

Risk Aversion Rules the Day: Which Currency Pairs Stand to Benefit?

After the Fed’s surprise move, the dust is getting settled. We are seeing serious reprising across many currency pairs. Sharp movements practically anywhere you look today. Where to start? With the euro, the yen or the Canadian dollar? It’s hard...
Nadia Simmons | March 22, 2019 |

Profiting on the Increasing Momentum in the Currencies

It looks like the calm in the currencies is drawing to a close and volatility is about to pick up. So far, so good. We’re at a crossroads these days: after a recent string of declines, the USD appears to be catching a bid. This is not without repercussions and ...
Nadia Simmons | June 13, 2019 |

Hawkish Rate Cut Sends Gold Prices Down

Yesterday, the Fed trimmed down the interest rates. This was widely expected – yet a blunt ruling out of an extended easing cycle wasn’t. The price of gold profoundly declined. Looking beneath the headline, what happened exactly? Fed Cuts Interest Rates by 2...
Arkadiusz Sieron | August 1, 2019 |

Can the Oil Bulls Succeed in Their Comeback Attempt After Yesterday’s Slide?

After several days of relative hesitation, oil did finally moved through and closed below an important support level, making our position immediately profitable. Can the bulls however mount a strong enough response to invalidate the breakdown? So far, it doesn’...
Przemyslaw Radomski, CFA | October 1, 2019 |

Wait… Was That a Bullish Silver Reversal?

Silver plunged on Tuesday, just as it was likely to after the triple reversal that we’ve been writing about , and it was declining strongly during Wednesday’s pre-market trading. And then it all changed. Silver soared before the U.S. markets op...
Przemyslaw Radomski, CFA | November 7, 2019 |

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. Yesterday evening,...
Streetwise Reports | December 16, 2019 |

The Opening Salvo in the Renewed Stock Downswing

As expected, the S&P 500 had a down session yesterday. Opening with a sizable gap, the bears continued their push to move prices lower. Since the futures have been pointing higher before the unemployment claims came in, does it mark a tradable turnaround? In short, that&C...
Monica Kingsley | April 2, 2020 |
1 2 3 4